Jennifer K. Moses - 01 Feb 2022 Form 4 Insider Report for G1 Therapeutics, Inc.

Role
CFO
Signature
/s/ James Stillman Hanson, attorney-in-fact
Issuer symbol
N/A
Transactions as of
01 Feb 2022
Net transactions value
+$9,579
Form type
4
Filing time
02 Feb 2022, 16:20:54 UTC
Previous filing
05 Jan 2022
Next filing
10 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $1,239 +333 +0.94% $3.72 35,888 01 Feb 2022 Direct F1
transaction GTHX Common Stock Options Exercise $8,340 +2,000 +5.6% $4.17 37,888 01 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Option (Right to Buy) Options Exercise $0 -2,000 -3.3% $0.000000 58,000 01 Feb 2022 Common Stock 2,000 $4.17 Direct F3
transaction GTHX Stock Options (Right to Buy) Options Exercise $0 -333 -100% $0.000000* 0 01 Feb 2022 Common Stock 333 $3.72 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents (i) 15,638 shares of common stock; (ii) 8,250 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022.
F2 Represents (i) 17,638 shares of common stock; (ii) 8,250 RSUs from award granted on January 4, 2021; and (iii) 12,000 RSUs from award granted on January 3, 2022.
F3 All shares underlying this option have vested.